An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets.
CRISPR screen
MANEC
NEC
WGS
gastric cancer
genetic screening
mouse model
neuroendocrine cancer
pharmacologic screening
stomach
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
10 07 2023
10 07 2023
Historique:
received:
20
09
2022
revised:
14
03
2023
accepted:
01
06
2023
medline:
13
7
2023
pubmed:
24
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
Gastric neuroendocrine carcinomas (G-NEC) are aggressive malignancies with poorly understood biology and a lack of disease models. Here, we use genome sequencing to characterize the genomic landscapes of human G-NEC and its histologic variants. We identify global and subtype-specific alterations and expose hitherto unappreciated gains of MYC family members in a large part of cases. Genetic engineering and lineage tracing in mice delineate a model of G-NEC evolution, which defines MYC as a critical driver and positions the cancer cell of origin to the neuroendocrine compartment. MYC-driven tumors have pronounced metastatic competence and display defined signaling addictions, as revealed by large-scale genetic and pharmacologic screening of cell lines and organoid resources. We create global maps of G-NEC dependencies, highlight critical vulnerabilities, and validate therapeutic targets, including candidates for clinical drug repurposing. Our study gives comprehensive insights into G-NEC biology.
Identifiants
pubmed: 37352862
pii: S1535-6108(23)00208-8
doi: 10.1016/j.ccell.2023.06.001
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1327-1344.e10Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.